2023年3月13日,医药界再掀波澜。赛诺菲(Sanofi)与Provention Bio联合发布声明,宣布双方已达成收购协议。赛诺菲将以近29亿美元的价格,全资收购Provention Bio,并一举将革命性的1型糖尿病延缓药物Teplizumab收入囊中。此次交易不仅为赛诺菲的产品线增添了一款“first-in-class”的T1D疗法,更彰显了公司在糖尿病治疗领域...
给药组与安慰剂组出现感染的发生率相近。 2023年3月13日,赛诺菲(Sanofi)和Provention Bio联合宣布,两者达成协议,赛诺菲将斥资近29亿美元收购Provention,并囊获用于延缓1型糖尿病(T1D)发病的药物Teplizumab。本次交易为赛诺菲产品管线中增添了一款first-in-class的T1D疗法。赛诺菲表示将继续拓展其在糖尿病领域的能力,...
2023年3月13日,赛诺菲(Sanofi)和Provention Bio联合宣布,两者达成协议,赛诺菲将斥资近29亿美元收购Provention,并囊获用于延缓1型糖尿病(T1D)发病的药物Teplizumab。本次交易为赛诺菲产品管线中增添了一款first-in-class的T1D疗法。赛诺菲表示将继续拓展其在糖尿病领域的能力,最大限度地发挥Teplizumab作为变革性疗法的...
More information:Tzield phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in the New England Journal of Medicine. News release. Sanofi; October 18, 2023. Accessed Octobe...
Sanofi Tusamitamab ravtansine (SAR408701) mAb, ADC CEACAM5 Phase 3 Nonsmall cell lung cancer (NCT04154956) Astellas Pharma Inc Zolbetuximab Chimeric IgG1 Claudin-18.2 Phase 3 Gastric/gastro-esophageal junction adenocarcinoma (NCT03653507, NCT03504397) AstraZeneca Tremelimumab Human IgG2 CTLA-4 Ph...
Teplizumab (also known as PRV 031) is a humanised, Fc-engineered anti-CD3 monoclonal antibody, being developed by Provention Bio (a subsidiary of Sanofi), for